📰 J Ints Bio News
J Ints Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from J Ints Bio. Real-time updates on events, politics, business and more.
April 11, 2024
/PRNewswire/ -- J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8th...
December 5, 2023
/PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI JIN-A02 were...
September 13, 2023
/PRNewswire/ -- J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI JIN-A02 was presented at the 2023 IASLC...
July 31, 2023
/PRNewswire/ -- J INTS BIO announced the successful dosing of the first patient in its global multi-center Phase 1/2 clinical study of JIN-A02 on 31st July...
May 31, 2023
/PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for...
April 26, 2023
/PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered TKI JIN-A04 targeting NSCLC with HER2 exon 20 insertion...
February 7, 2023
/PRNewswire/ -- J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibitor (TKI) targeting HER2 Exon20 insertion...
September 16, 2022
/PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI JIN-A02 at the ESMO 2022, that showed...
August 19, 2022
/PRNewswire/ -- J INTS BIO announced that it held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR-TKI JIN-A02 on the...
August 16, 2022
/PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI JIN-A02 was presented on the 8th of...